Home › Insufficienza cardiaca › Missouri › Kansas City
Studi clinici su Insufficienza cardiaca a Kansas City, MO
25 studi su Insufficienza cardiaca cercano partecipanti presso sedi a Kansas City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
ELEVATE-HFpEF Clinical Study
In reclutamento
- Saint Lukes Mid America Heart Institute, Kansas City
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
In reclutamentoFase 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
In reclutamentoFase 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · a 2 mi di distanza
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
In reclutamentoFase 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
In reclutamentoFase 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
In reclutamentoFase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
In reclutamento
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
In reclutamentoFase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
In reclutamentoFase 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
In reclutamentoFase 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
In reclutamentoFase 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
In reclutamentoStudio osservazionale
- St. Luke's Hospital of Kansas City, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
In reclutamentoFase 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
In reclutamentoStudio osservazionale
- Kansas City, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
In reclutamentoStudio osservazionale
- St. Luke's Mid-America Heart Institute, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
In reclutamentoFase 3
- Tenax Investigational Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
In reclutamentoFase 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
In reclutamento
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
In reclutamentoFase 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
In reclutamento
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
In reclutamentoFase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
In reclutamentoFase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
In reclutamento
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
In reclutamentoStudio osservazionale
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
In reclutamentoStudio osservazionale
- Saint Luke's Health System, Kansas City
Studi su Insufficienza cardiaca in altre città
- New York City, NY51 studi
- Boston, MA44 studi
- Dallas, TX42 studi
- Houston, TX36 studi
- Cleveland, OH33 studi
- Chicago, IL31 studi
- Philadelphia, PA31 studi
- San Francisco, CA29 studi
- Durham, NC26 studi
- St. Louis, MO26 studi
- Atlanta, GA25 studi
- Cincinnati, OH24 studi
Altri studi a Kansas City
- Cancro al seno34 studi
- Cancro del polmone non a piccole cellule31 studi
- Cancro (tutti i tipi)21 studi
- Cancro ai polmoni19 studi
- Cancro colorettale16 studi
- Cancro metastatico15 studi
- Leucemia mieloide acuta15 studi
- Cancro alla prostata14 studi
- Cancro ovarico11 studi
- Obesità11 studi
- Diabete di tipo 211 studi
- Malattie cardiovascolari11 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.